Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Triamcinolone
Drug ID BADD_D02271
Description Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis.[L8255] Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain,[L8264] or first line as a topical treatment of corticosteroid responsive dermatoses.[L8249] Triamcinolone is more commonly seen in the forms triamcinolone hexacetonide, triamcinolone acetonide, and triamcinolone diacetate.[L8246,L8249,L8252,L8255,L8258,L8261,L8264] Triamcinolone was granted FDA approval on 3 December 1957.[L8243] In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection - the first suprachoroidal injection to receive FDA approval[L38973] - for the treatment of patients with macular edema associated with uveitis.[L38963]
Indications and Usage For the treatment of perennial and seasonal allergic rhinitis.
Marketing Status Discontinued
ATC Code A01AC01; C05AA12; D07AB09; D07XB02; H02AB08; R01AD11; R03BA06; S01BA05
DrugBank ID DB00620
KEGG ID D00385
MeSH ID D014221
PubChem ID 31307
TTD Drug ID D03BLF
NDC Product Code 22552-0003; 46439-8701; 38779-0051; 51927-1049
Synonyms Triamcinolone | Volon | Aristocort
Chemical Information
Molecular Formula C21H27FO6
CAS Registry Number 124-94-7
SMILES CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Malignant melanomaSerotransferrinP02787T026173015380; 2737997; 3919942; 6850583; 2788234; 2788497; 3297308; 6424929; 2439521; 6454570; 3049518; 6983291; 8826092; 6273246
Malignant melanomaInsulinP01308T828413015380; 2737997; 3919942; 6850583; 2788234; 2788497; 3297308; 6424929; 2439521; 6454570; 3049518; 6983291; 8826092; 6273246
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Oedema08.01.07.006; 14.05.06.0100.000126%Not Available
Optic neuritis06.04.08.002; 17.04.05.001; 10.04.10.002--Not Available
Osteoarthritis15.01.04.001--Not Available
Osteonecrosis24.04.05.004; 15.02.04.007--
Osteoporosis15.02.03.002; 14.04.04.002--
Pain08.01.08.0040.001012%
Pain in extremity15.03.04.010--
Palpitations02.01.02.0030.000316%
Pancreatitis07.18.01.001--
Papilloedema24.03.07.001; 17.07.02.004; 06.09.02.002--
Paraesthesia17.02.06.005--
Paraparesis17.01.04.006--Not Available
Paraplegia17.01.04.007--Not Available
Peptic ulcer07.04.07.001--Not Available
Personality change19.05.01.006; 17.02.05.019--
Petechiae24.07.06.004; 23.06.01.003; 01.01.03.002--Not Available
Pharyngitis22.07.03.004; 11.01.13.003; 07.05.07.004--
Pollakiuria20.02.02.0070.000253%
Pruritus23.03.12.0010.000506%
Pulmonary oedema22.01.03.003; 02.05.02.003--
Purpura23.06.01.004; 24.07.06.005; 01.01.04.003--
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Rash generalised23.03.13.0020.000126%Not Available
Rash macular23.03.13.0030.000126%Not Available
Rash pruritic23.03.12.0020.000126%Not Available
Retinal detachment12.01.04.004; 06.09.03.0030.000696%
Rhinitis22.07.03.006; 11.01.13.004--
Rhinorrhoea22.02.05.0100.000126%
Scar23.03.11.008; 12.01.06.0080.000126%Not Available
The 6th Page    First    Pre   6 7 8 9    Next   Last    Total 9 Pages